Protective effect of lipoic acid against methylglyoxal-induced oxidative stress in LLC-PK1 cells

Journal of Nutritional Science and Vitaminology

Volumn 54, Issue 1, 2008, Pages 99-104

  Kim, Hyun Young ^a   Oi, Yasuyuki ^b   Kim, Mujo ^b   Yokozawa, Takako ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Pharma Foods International Co Ltd   (Japan)

Author keywords

Lipoic acid; NF B; NO; Oxidative stress; Reactive oxygen species

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLGLYOXAL; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; THIOCTIC ACID;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; KIDNEY TUBULE CELL; NONHUMAN; OXIDATIVE STRESS;

ANIMALS; ANTIOXIDANTS; CELL CULTURE TECHNIQUES; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; KIDNEY TUBULES; LLC-PK1 CELLS; NF-KAPPA B; NITRIC OXIDE; OXIDATIVE STRESS; PYRUVALDEHYDE; REACTIVE OXYGEN SPECIES; SWINE; THIOCTIC ACID;

EID: 40949158539     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.54.99     Document Type: Article

References (43)

1. Thornalley PJ, Langborg A, Minhas HS. 1999. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344: 109-116.
2. Ahmed N. 2005. Advanced glycation endproducts - role in pathology of diabetic complications. Diabetes Res Clin Pract 67: 3-21.
3. Baynes JW, Thorpe SR. 1999. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48: 1-9.
4. Odani H, Shinzato T, Matsumoto Y, Usami J, Maeda K. 1999. Increase in three alpha, beta-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem Biophys Res Commun 256: 89-93.
5. Blakytny R, Harding JJ. 1992. Glycation (non-enzymic glycosylation) inactivates glutathione reductase. Biochem J 288: 303-307.
6. Paget C, Lecomte M, Ruggiero D, Wiernsperger N, Lagarde M. 1998. Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products. Free Radic Biol Med 25: 121-129.
7. Packer L, Witt EH, Tritschler HJ. 1995. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 19: 227-250.
8. Khanna S, Atalay M, Laaksonen DE, Gul M, Roy S, Sen CK. 1999. Alpha-lipoic acid supplementation: tissue glutathione homeostasis at rest and after exercise. J Appl Physiol 86: 1191-1196.
9. Suh JH, Shigeno ET, Morrow JD, Cox B, Rocha AE, Frei B, Hagen TM. 2001. Oxidative stress in the aging rat heart is reversed by dietary supplementation with (R)-(alpha)-lipoic acid. FASEB J 15: 700-706.
10. Morini M, Roccatagliata L, Dell'Eva R, Pedemonte E, Furlan R, Minghelli S, Giunti D, Pfeffer U, Marchese M, Noonan D, Mancardi G, Albini A, Uccelli A. 2004. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol 148: 146-153.
11. Konrad T, Vicini P, Kusterer K, Hoflich A, Assadkhani A, Bohles HJ, Sewell A, Tritschler HJ, Cobelli C, Usadel KH. 1999. Alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 22: 280-287.
12. Kowluru RA, Odenbach S. 2004. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 53: 3233-3238.
13. Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Moller W, Tritschler HJ, Mehnert H. 1999. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha lipoic acid in diabetic neuropathy. Free Radic Res 31: 171-179.
14. Malarkodi KP, Balachandar AV, Varalakshmi P. 2003. The influence of lipoic acid on adriamycin induced nephrotoxicity in rats. Mol Cell Biochem 247: 15-22.
15. Sivaprasad R, Nagaraj M, Varalakshmi P. 2004. Combined efficacies of lipoic acid and meso 2,3-dimercaptosuccinic acid against lead induced lipid peroxidation in rat liver. J Nutr Biochem 15: 18-23.
16. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. 1987. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942.
17. Wang H, Joseph JA. 1999. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med 27: 612-616.
18. Cho KJ, Han SH, Kim BY, Hwang SG, Park KK, Yang KH, Chung AS. 2000. Chlorophyllin suppression of lipopolysaccharide-induced nitric oxide production in RAW 264.7 cells. Toxicol Appl Pharmacol 166: 120-127.
19. Beisswenger PJ, Howell SK, Nelson RG, Mauer M, Szwergold BS. 2003. Alpha-oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans 31: 1358-1363.
20. Lo T, Westwood M, McLellan A, Selwood T, Thornalley P. 1994. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with Nα-acetylarginine, Nα-acetylcysteine, and Nα-acetyllysine, and bovine serum albumin. J Biol Chem 269: 32299-32305.
21. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H. 1995. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44: 824-829.
22. Thornalley P. 1996. Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab 3: 149-166.
23. Kagan VE, Shvedova A, Serbinova E, Khan S, Swanson C, Powell R, Packer L. 1992. Dihydrolipoic acid - a universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxyl, ascorbyl and chromanoxyl radicals. Biochem Pharmacol 44: 1637-1649.
24. Breithaupt-Grogler K, Niebch G, Schneider E, Erb K, Hermann R, Blume HH, Schug BS, Belz G. 1999. Dose-proportionality of oral thioctic acid - coincidence of assessments via pooled plasma and individual data. Eur J Pharm Sci 8: 57-65.
25. Pick U, Haramaki N, Constantinescu A, Handelman GJ, Tritschler HJ, Packer L. 1995. Glutathione reductase and lipoamide dehydrogenase have opposite stereospecificities for α-lipoic acid enantiomers. Biochem Biophys Res Commun 206: 724-730.
26. Dong J, Ramachandiran S, Tikoo K, Jia Z, Lau SS, Monks TJ. 2004. EGFR-independent activation of p38 MAPK and EGFR-dependent activation of ERK1/2 is required for ROS-induced renal cell death. Am J Physiol Renal Physiol 87: F1049-F1058.
27. Lee HC, Yin PH, Lu CY, Chi CW, Wei YH. 2000. Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells. Biochem J 348: 425-432.
28. Yim HS, Kang SO, Hah YC, Chock PB, Yim MB. 1995. Free radicals generated during the glycation reaction of amino acids by methylglyoxal. A model study of protein-cross-linked free radicals. J Biol Chem 270: 28228-28233.
29. Ward RA, McLeish KR. 2004. Methylglyoxal: a stimulus to neutrophil oxygen radical production in chronic renal failure? Nephrol Dial Transplant 19: 1702-1707.
30. Yaqoob M, McClelland P, Patrick AW, Stevenson A, Mason H, White MC, Bell GM. 1994. Evidence of oxidant injury and tubular damage in early diabetic nephropathy. QJM 87: 601-607.
31. Cobb JP, Hotchkiss RS, Karl IE, Buchman TG. 1996. Mechanisms of cell injury and death. Br J Anaesth 77: 3-10.
32. Beckman JS, Koppenol WH. 1996. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271: C1424-C1437.
33. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. 1990. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620-1624.
34. Corbett JA, McDaniel ML. 1992. Does nitric oxide mediate autoimmune destruction on β-cells? Possible therapeutic interventions in IDDM. Diabetes 41: 897-903.
35. Demarco VG, Scumpia PO, Bosanquet JP, Skimming JW. 2004. Alpha-lipoic acid inhibits endotoxin-stimulated expression of iNOS and nitric oxide independent of the heat shock response in RAW 264.7 cells. Free Radic Res 38: 675-682.
36. 2 synthesis in RAW 264.7 macrophages through the inhibition of iNOS and COX-2 gene expression. Life Sci 75: 675-684.
37. Baldwin AS Jr. 1996. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14: 649-681.
38. Grimm S, Bauer MK, Baeuerle PA, Schulze-Osthoff K. 1996. Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis. J Cell Biol 134: 13-23.
39. Bayon Y, Alonso A, Sanchez Crespo M. 1999. 4-Trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4- trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor kappa B activation. Br J Pharmacol 126: 1359-1366.
40. Shishodia S, Majumdar S, Banerjee S, Aggarwal BB. 2003. Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res 63: 4375-4383.
41. Wu L. 2005. The pro-oxidant role of methylglyoxal in mesenteric artery smooth muscle cells. Can J Physiol Pharmacol 83: 63-68.
42. Suzuki YJ, Aggarwal BB, Packer L. 1992. Alpha-lipoic acid is a potent inhibitor of NF-kappa B activation in human T cells. Biochem Biophys Res Commun 189: 1709-1715.
43. Kim HJ, Chang EJ, Kim HM, Lee SB, Kim HD, Kim GS, Kim HH. 2006. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha. Free Radic Biol Med 40: 1483-1493.